We are live on ! Find out more
EPZM

Epizyme, Inc

Delisted

EPZM was delisted on the 11th of August, 2022.

137 hedge funds and large institutions have $832M invested in Epizyme, Inc in 2021 Q1 according to their latest regulatory filings, with 18 funds opening new positions, 51 increasing their positions, 41 reducing their positions, and 15 closing their positions.

New
Increased
Maintained
Reduced
Closed

1,192% more call options, than puts

Call options by funds: $22.3M | Put options by funds: $1.73M

24% more repeat investments, than reductions

Existing positions increased: 51 | Existing positions reduced: 41

20% more first-time investments, than exits

New positions opened: 18 | Existing positions closed: 15

0% more funds holding

Funds holding: 137137 (0)

14% less funds holding in top 10

Funds holding in top 10: 76 (-1)

20% less capital invested

Capital invested by funds: $1.04B → $832M (-$212M)

Holders
137
Holders Change
Holders Change %
0%
% of All Funds
2.41%
Holding in Top 10
6
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-14.29%
% of All Funds
0.11%
New
18
Increased
51
Reduced
41
Closed
15
Calls
$22.3M
Puts
$1.73M
Net Calls
+$20.6M
Net Calls Change
-$6.19M
Name Holding Trade Value Shares
Change
Change in
Stake
Primecap Management
1
Primecap Management
California
$133M +$296K +28,600 +0.2%
RM
2
RP Management
New York
$79.8M
RG
3
Redmile Group
California
$76.9M -$6.48M -625,939 -7%
BlackRock
4
BlackRock
New York
$73.1M +$4.98M +481,030 +6%
Vanguard Group
5
Vanguard Group
Pennsylvania
$68.2M +$2.74M +264,731 +3%
PAI
6
Palo Alto Investors
California
$59.7M +$1.22M +117,600 +2%
State Street
7
State Street
Massachusetts
$49.4M +$14M +1,352,931 +31%
KXA
8
KPCB XIII Associates
California
$33.4M
RSCM
9
Rock Springs Capital Management
Maryland
$24.4M +$2.58M +249,746 +10%
MB
10
MPM BioImpact
Massachusetts
$20.3M
Morgan Stanley
11
Morgan Stanley
New York
$16.4M +$101K +9,795 +0.5%
Fidelity Investments
12
Fidelity Investments
Massachusetts
$15.7M +$1.51M +146,407 +9%
Geode Capital Management
13
Geode Capital Management
Massachusetts
$13.9M +$1.59M +153,464 +11%
GIM
14
Granahan Investment Management
Massachusetts
$10.3M +$3.39M +327,976 +38%
FCMI
15
Foresite Capital Management II
California
$8.71M
FCMI
16
Foresite Capital Management III
California
$8.7M
Northern Trust
17
Northern Trust
Illinois
$8.31M -$506K -48,908 -5%
T. Rowe Price Associates
18
T. Rowe Price Associates
Maryland
$8.19M -$6.23M -602,356 -39%
Norges Bank
19
Norges Bank
Norway
$7.89M -$1.43M -138,142 -13%
Dimensional Fund Advisors
20
Dimensional Fund Advisors
Texas
$7.46M -$618K -59,769 -7%
CIBC Private Wealth Group
21
CIBC Private Wealth Group
Georgia
$7.38M +$895K +86,500 +11%
FM
22
Frazier Management
Washington
$6.44M +$82.1K +7,933 +1%
VOYA Investment Management
23
VOYA Investment Management
Georgia
$6.27M -$1.2M -115,834 -14%
Goldman Sachs
24
Goldman Sachs
New York
$6.2M +$888K +85,781 +14%
Charles Schwab
25
Charles Schwab
California
$5.46M +$197K +19,032 +3%

EPZM Hedge Fund Activity: Q1 2021 in Review

137 of the 5,695 institutional investors tracked by Wall St. Rank reported a position in Epizyme, Inc (EPZM) for Q1 2021, worth a combined $832M — down 20% from $1.04B a quarter earlier.

Buyers outnumbered sellers: 18 funds opened new EPZM positions and 15 closed out — a net gain of 3 holders — while 51 added to existing stakes and 41 trimmed.

The largest buyer was State Street, adding an estimated $14M. The largest seller was Victory Capital Management, cutting an estimated $27.5M.

  • 137 institutional investors held Epizyme, Inc (EPZM) as of Q1 2021, unchanged from Q4 2020.
  • Funds reported $832M of Epizyme, Inc stock for Q1 2021, down 20% quarter-over-quarter.
  • 18 funds opened new Epizyme, Inc positions in Q1 2021 and 15 closed out, a net change of +3 holders.
  • The largest Epizyme, Inc buyer in Q1 2021 was State Street, an estimated $14M added.
  • The largest Epizyme, Inc seller in Q1 2021 was Victory Capital Management, an estimated $27.5M sold.

Based on aggregated 13F filings for Q1 2021.